Introduction {#s1}
============

SOX2 (sex determining region Y-box 2) is a transcription factor necessary for embryonic stem cell (ESC) self-renewal ([@bib2]; [@bib25]). Precise control of SOX2 is critical for ESC maintenance, since increased or decreased expression of SOX2 interferes with self-renewal and pluripotency ([@bib22]; [@bib25]). Post-translational modifications (PTMs) of SOX2 may play a role in its regulation, as SOX2 is reported to be phosphorylated, methylated, ubiquitinylated, SUMOylated, acetylated, and PARylated ([@bib5]; [@bib7]; [@bib12]; [@bib15]; [@bib23]; [@bib34]; [@bib35]; [@bib38]; [@bib39]; [@bib43]).

We have previously shown SOX2 is *O-*linked *N*-acetlyglucosamine (*O*-GlcNAc) modified in mouse ESCs (mESCs) ([@bib26]). *O-*GlcNAcylation is the dynamic and regulatory mono-glycosylation of nucleocytosolic proteins catalyzed by a single *O-*GlcNAc transferase (OGT) and removed by a single hydrolase (OGA/MGEA5/NCOAT). *O-*GlcNAc signaling is essential for embryo viability ([@bib28]; [@bib33]; [@bib40]) and mESC self-renewal ([@bib20]). While OGT is critical for mESC maintenance, the protein- and site-specific functions of *O-*GlcNAcylation in mESCs have not been fully elucidated.

Here, we show that *O*-GlcNAcylation of SOX2 at serine 248 (S248) is dynamically regulated in mESCs. Upon differentiation, *O*-GlcNAc occupancy is reduced and SOX2 is predominantly unmodified at this site. Replacement of wild type SOX2 (SOX2^WT^) with an *O-*GlcNAc-deficient mutant SOX2 (SOX2^S248A^) results in increased reprogramming efficiency. mESCs with SOX2^S248A^ as their sole source of SOX2 have increased expression of genes associated with pluripotency and exhibit a decreased requirement for OCT4. SOX2^S248A^ exhibits altered genomic occupancy and differential association with transcriptional regulatory complexes. *O*-GlcNAcylation directly inhibits the SOX2 and PARP1 interaction, which plays a regulatory role in mESC pluripotency ([@bib15]; [@bib23]). This study implicates *O*-GlcNAc modification in coordinating genomic occupancy and protein-protein interactions of SOX2 in ESCs, and provides molecular insight into how this broadly expressed transcription factor is regulated to promote the pluripotency-specific expression program.

Results {#s2}
=======

SOX2 *O*-GlcNAcylation is regulated by differentiation cues {#s2-1}
-----------------------------------------------------------

Previously, we reported in mESCs SOX2 was *O*-GlcNAcylated in the transactivation domain (TAD) ([@bib26]), a region described to possess several other PTMs ([@bib7]; [@bib34]; [@bib35]; [@bib38]; [@bib39]). To investigate whether PTMs in the TAD are subject to developmental regulation, we analyzed SOX2 during the initial stages of differentiation. Knock-in FLAG/HA tagged SOX2 mESCs (KI cells; [@bib23]) were cultured in media containing MEK and GSK3b inhibitors (2i) and leukemia inhibitory factor (LIF), or were induced to differentiate by removing LIF and adding retinoic acid (RA). Liquid chromatography coupled with tandem mass spectrometric (LC-MS/MS) analysis of SOX2 in self-renewal conditions revealed four main populations of the TAD peptide containing serine 248 (hereinafter referred to as TAD peptide): unmodified, *O*-GlcNAcylated at one of two sites (S248 or T258), phosphorylated at S253, and doubly modified with *O*-GlcNAcylation at S248 and phosphorylation at S253, ([Figure 1A---figure supplements 1](#fig1s1){ref-type="fig"}--[5](#fig1s5){ref-type="fig"}). Removal of LIF and addition of RA for 48 hr resulted in a marked decrease in the *O*-GlcNAc occupancy of the TAD peptide with no change in the phosphorylation stoichiometry ([Figure 1B--C](#fig1){ref-type="fig"}). These data indicate *O*-GlcNAcylation of SOX2 S248 is responsive to differentiation cues.10.7554/eLife.10647.003Figure 1.SOX2 *O*-GlcNAc levels change during differentiation.(**A**) Diagram of SOX2 (bottom, with TAD and high mobility group DNA binding domain \[HMG\] indicated), the TAD peptide sequence (middle; amino acid numbering from the Uniprot accession number P48432), and the PTM isoforms identified on the TAD peptide (top, grey and white rectangles, g indicates *O*-GlcNAc and p indicates phosphate). Mass spectra can be seen in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. (**B**) and (**C**) Extracted ion chromatographs (XICs) of SOX2 TAD peptide PTM states from (**B**) undifferentiated KI SOX2 mESCs (2i+L) or (**C**) differentiated KI SOX2 mESCs (RA 48 hr). Traces for each PTM isoform are colored differently, key provided in the inset in (**B**).**DOI:** [http://dx.doi.org/10.7554/eLife.10647.003](10.7554/eLife.10647.003)10.7554/eLife.10647.004Figure 1---figure supplement 1.ETD**-**MS/MS spectra of SOX2 unmodified TAD peptide described in [Figure 1A](#fig1){ref-type="fig"}.Proton transfer species are not labeled, ppm, parts per million; b.p., base peak.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.004](10.7554/eLife.10647.004)10.7554/eLife.10647.005Figure 1---figure supplement 2.ETD**-**MS/MS spectra of SOX2 GlcNAc-S248 TAD peptide described in [Figure 1A](#fig1){ref-type="fig"}.Proton transfer species are not labeled, ppm, parts per million; b.p., base peak.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.005](10.7554/eLife.10647.005)10.7554/eLife.10647.006Figure 1---figure supplement 3.ETD**-**MS/MS spectra of SOX2 GlcNAc-T258 TAD peptide described in [Figure 1A](#fig1){ref-type="fig"}.Proton transfer species are not labeled, ppm, parts per million; b.p., base peak.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.006](10.7554/eLife.10647.006)10.7554/eLife.10647.007Figure 1---figure supplement 4.ETD**-**MS/MS spectra of SOX2 phospho-S253 TAD peptide described in [Figure 1A](#fig1){ref-type="fig"}.Proton transfer species are not labeled, ppm, parts per million; b.p., base peak.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.007](10.7554/eLife.10647.007)10.7554/eLife.10647.008Figure 1---figure supplement 5.ETD-MS/MS spectra of SOX2 co-modified GlcNAc-S248/phospho-S253 TAD peptide described in [Figure 1A](#fig1){ref-type="fig"}.Proton transfer species are not labeled, ppm, parts per million; b.p., base peak, † indicates co-isolating contamination peak.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.008](10.7554/eLife.10647.008)10.7554/eLife.10647.009Figure 1---figure supplement 6.*O*-GlcNAcylation of OCT4 at T228 is undetectable in mESCs.OCT4 was FLAG-affinity purified from ZHBTc4 F-Oct4 ESCs (the same cell line employed in \[[@bib20]\]), which express FLAG-tagged OCT4. Peptides containing T228, the residue reported to be *O*-GlcNAcylated ([@bib20]), were analyzed by LC-MS/MS. (**A**) XICs (10 ppm) for predicted m/z of an unmodified tryptic peptide containing T228 (top, black panel) and the proposed *O*-GlcNAc modified peptide (bottom, red panel). XICs show the signal for the unmodified peptide, but no signal for the *O*-GlcNAc modified version. (**B**) XICs (10 ppm) for m/z of predicted *O*-GlcNAc modified LysC-derived peptides containing T228 is not detectable (two charge states, with and without Met oxidation). (**C**) Zoom of MS1 scans from Figure supplement 6B where potential signal would exists. No signal with the appropriate charge state was detected for any LysC derived peptide indicating all signal in B is background. (**D**) Western blot analysis of purified FLAG-tagged OCT4 from ZHBT c4 F-OCT4 mESCs failed to detect O-GlcNAcylation. (**E**) Western blot analysis of 3xF-SOX2 purified from OS^FLAG-WT^KM transduced MEFs detects SOX2 *O*-GlcNAcylation, which can be blocked by the addition of 100 mM free GlcNAc to the primary antibody incubation.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.009](10.7554/eLife.10647.009)10.7554/eLife.10647.010Figure 1---figure supplement 7.Incorrect assignment of GluC digest OCT4 peptide mass spectrum containing T228.(**A**) Modified mass spectrum from Jang *et al.* identifying OCT4 T228 as *O*-GlcNAc modified ([Figure 3D](#fig3){ref-type="fig"}; Cell Stem Cell 17 May 2012 \[doi: 10.1016/j.stem.2012.03.001\]). Problematic issues are 1) discrepancy with well-established fragmentation patterns for *O*-linked glycopeptides; 2) confusing labeling of peaks (original black arrows, which obscured peak identifications, were changed to green for this figure); 3) incorrect peptide sequence. GluC digestion should yield ICKSETLVQARKRKRTSIE, where the initial Ile is missing from the Jang *et al*. assignment; 4) only OCT4 peptide sequences were searched increasing false positive rates; and 5) the precursor mass and charge state were not reported making the data uninterpretable. (**B**) Ion trap CAD mass spectrum of synthetic glycopeptide of the reported amino acid sequence shows the original spectrum in Jang *et al*. was misinterpreted.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.010](10.7554/eLife.10647.010)

In mESCs SOX2 heterodimerizes with OCT4, which is also reported to be *O*-GlcNAcylated in this cell type ([@bib20]). Thus, it is possible that OGT targets both these transcription factors when they are complexed together, prompting us to query OCT4 O-GlcNAcylation. However, we were unable to detect OCT4 *O*-GlcNAcylation in mESCs ([Figure 1---figure supplements 6](#fig1s6){ref-type="fig"}--[7](#fig1s7){ref-type="fig"}).

*O*-GlcNAc-deficient SOX2 increases somatic cell reprogramming efficiency {#s2-2}
-------------------------------------------------------------------------

To query whether *O*-GlcNAcylation at S248 is present in other contexts, we examined the PTM profile of the SOX2 TAD peptide during somatic cell reprogramming. We used four-factor retroviral reprogramming (*Oct4, Sox2, Klf4* and *Myc*; OSKM) in which SOX2 contained a triple FLAG tag (OS^FLAG-WT^KM). LC-MS/MS analysis of purified SOX2 six days after transduction of mouse embryonic fibroblasts (MEFs) showed S248 is *O*-GlcNAcylated ([Figure 2A](#fig2){ref-type="fig"}). In addition, mutation of S248 to alanine (S248A) resulted in loss of *O*-GlcNAcylation without affecting the other PTMs of the TAD peptide ([Figure 2B--C](#fig2){ref-type="fig"}). These results demonstrate S248 is *O*-GlcNAc modified during somatic cell reprogramming and suggest a connection between this SOX2 PTM and pluripotency.10.7554/eLife.10647.011Figure 2.*O*-GlcNAc-deficient SOX2, SOX2^S248A^, increases somatic cell reprogramming efficiency.(**A**) Diagram of SOX2 and the PTMs identified from MEFs transduced with OS^FLAG-WT^KM, labeled as described in [Figure 1A](#fig1){ref-type="fig"}. Spectra can be found at *tinyurl.com/iPSC-3xF-SOX2-ETD* and *tinyurl.com/iPSC-3xF-SOX2-HCD*. (**B**) XICs of 3xF-SOX2^WT^ TAD peptide PTM states from OS^FLAG-WT^KM-transduced MEFs. (**C**) XICs of 3xF-SOX2^S248A^ TAD peptide PTM states from OS^FLAG-S248A^KM-transduced MEFs. Color key the same as in (**B**). (**D**) Number of GFP^+^ colonies from 1000 *Nanog-Gfp* MEFs transduced with OS^WT^KM or OS^S248A^KM and cultured on SNL feeders for 18 or 20 days (n=7 +/- S.E.M.). (**E**) Chimeric mouse derived from iPSCs obtained from transducing *Nanog-Gfp* MEFs with OS^S248A^KM and his black offspring, demonstrating germline transmission. (**F**) Western blots against FLAG, SOX2, OGT and TUBULIN for the first six days of reprogramming with either OS^FLAG-WT^KM or OS^FLAG-S248A^KM. "Endo" refers to the apparent molecular weight at which the endogenous SOX2 would be expected, "3xF" refers the the FLAG tagged version from the viral transduction.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.011](10.7554/eLife.10647.011)10.7554/eLife.10647.012Figure 2---figure supplement 1.Immunofluorescence staining against FLAG in MEFs six days after transduction with either OS^FLAG-WT^KM or OS^FLAG-S248A^KM shows similar nucleocytoplasmic distribution.E14 mESCs are used as a staining negative control.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.012](10.7554/eLife.10647.012)10.7554/eLife.10647.013Figure 2---figure supplement 2.SOX2^S248D^ also increases somatic cell reprogramming efficiency.Relative increase, compared to OS^WT^KM, in number of GFP^+^ colonies from 1000 *Nanog-Gfp* MEFs that were infected with OS^S248A^KM or the phosphomimetic OS^S248D^KM and cultured on SNL feeders for 20 days after infection (n=7 for OS^WT^KM and OS^S248A^KM, two for OS^S248D^KM).**DOI:** [http://dx.doi.org/10.7554/eLife.10647.013](10.7554/eLife.10647.013)

To determine whether the S248A mutation impacted induced pluripotent stem cell (iPSC) colony formation, we used somatic cell reprogramming of *N*a*nog-Gfp* reporter MEFs ([@bib36]). *N*a*nog-Gfp* MEFs transduced with OS^S248A^KM produced significantly more GFP^+^ iPSC colonies compared to OS^WT^KM ([Figure 2D](#fig2){ref-type="fig"}). iPSCs generated with OS^S248A^KM exhibited standard colony morphology and contributed to chimeric mice capable of germ line transmission ([Figure 2E](#fig2){ref-type="fig"}), indicating these OS^S248A^KM iPSCs exhibit the features of normal iPSCs. By Western blot and immunostaining of MEFs transduced with OS^FLAG-WT^KM or OS^FLAG-S248A^KM showed equal levels of exogenous SOX2 for the first six days ofof reprogramming ([Figure 2F](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), indicating comparable expression of WT and S248A triple FLAG tagged SOX2. OGT levels were also similar for the first six days of reprogramming between OS^FLAG-WT^KM and OS^FLAG-S248A^KM transduced MEFs ([Figure 2F](#fig2){ref-type="fig"}). These results indicate that SOX2^S248A^ is more efficient than wild type SOX2 at inducing pluripotency and suggest *O*-GlcNAcylation at S248 inhibits SOX2 activity.

The homologous SOX2 residue has been reported to be phosphorylated in human ESCs ([@bib34]). While our lab and others were unable to detect this phosphorylation in mESCs ([@bib7]) or during murine reprogramming, the S248A mutation could potentially remove a regulatory phosphorylation site. Therefore, we performed reprogramming experiments using the phospho-mimetic SOX2 mutant, S248D. This mutation also increased reprogramming efficiency ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), suggesting it is the removal of an *O*-GlcNAcylation site, and not of a phosphorylation site, which mediates the effect on SOX2 activity.

SOX2^S248A^ can replace wild type SOX2 in mESCs {#s2-3}
-----------------------------------------------

Since the reprogramming results suggested the S248A mutation increased SOX2 activity, we examined whether this mutant SOX2 supported mESC self-renewal. We generated mESC lines that express either a FLAG-tagged wild-type *Sox2* transgene (fSOX2-Tg cells) or an S248A transgene (fS248A-Tg cells) ([Figure 3A](#fig3){ref-type="fig"}). We introduced the transgenes into 2TS22C mESCs, in which endogenous *Sox2* is removed and a doxycycline repressible SOX2 cDNA transgene supports self-renewal ([@bib25])([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Under doxycycline repression, the sole source of SOX2 in these transgenic lines is the FLAG-tagged wild-type or S248A mutant SOX2 ([Figure 3B](#fig3){ref-type="fig"}). SOX2 levels in fSOX2-Tg and fS248A-Tg mESCs are comparable to SOX2 levels in the 2TS22C parental cell line and nucleo-cytoplasmic distribution was not altered by the mutation ([Figure 3C](#fig3){ref-type="fig"}). OCT4 and NANOG abundance and distribution were comparable between fSOX2-Tg and fS248A-Tg mESCs ([Figure 3C](#fig3){ref-type="fig"}), arguing that there is no gross effect on these pluripotency transcription factors.10.7554/eLife.10647.014Figure 3.SOX2^S248A^ can replace wild type SOX2 in mESCs.(**A**) Characterization of fSOX2-Tg and fS248A-Tg mESCs. fSOX2-Tg and fS248A-Tg mESCs exhibit AP staining, a marker of pluripotency, similar to parental 2TS22C cells. (**B**) Western blot analysis of SOX2 and FLAG in 2TS22C, fSOX2-Tg and fS248A-Tg mESCs. TUBULIN (TUB) is used as a loading control. "3xFLAG" and "untagged" refer to expected molecular weights of SOX2 with the 3xFLAG tag or no tag, respectively. (**C**) Immunofluorescence staining for NANOG, SOX2, FLAG and OCT4 in wild type E14, parental 2TS22C, fSOX2-Tg, and fS248A-Tg mESCs. Antibody staining is green, nuclear stain with DAPI is blue. (**D**) and (**E**) XICs of the TAD peptides of SOX2 immunopurified from fSOX2-Tg (**D**) and fS248A-Tg (**E**) mESCs. Insets: pie charts showing the mean percentage of each PTM form to total TAD peptide signal (n=3). The doubly phosphorylated TAD peptide is below the limit of quantitation for both cell lines.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.014](10.7554/eLife.10647.014)10.7554/eLife.10647.015Figure 3---figure supplement 1.Diagram of creation of fSOX2-Tg or fS248A-Tg lines.(**A**) Derivation of 2TS22C mESCs, which are deleted for endogenous copies of *Sox2* and express tetracycline-off (tet-off) transgenic *Sox2*, summarized from ([@bib25]). (**B**) 2TS22C cells were transfected with the constructs pCAG-3xF-SOX2^WT^-IRES-puro^R^ (upper) or pCAG-3xF-SOX2^S248A^-IRES-puro^R^ (lower), in which *Sox2* expression is driven by the CAG promoter. After 24 hr, doxycycline was added to cultures to repress the tet-regulated copy of SOX2 expressed by the parental line 2TS22C. 48 hr after transfection, puromycin was added to cultures to select for stable integrants. After two weeks, colonies with ESC-like colony morphology were expanded and characterized for SOX2 expression.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.015](10.7554/eLife.10647.015)10.7554/eLife.10647.016Figure 3---figure supplement 2.Diagram of SOX2 and the PTMs identified from fSOX2-Tg cells, labeled as described in [Figure 1A](#fig1){ref-type="fig"}.Spectra can be found at *tinyurl.com/3xF-SOX2-ETD* and *tinyurl.com/3xF-SOX2-HCD*.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.016](10.7554/eLife.10647.016)10.7554/eLife.10647.017Figure 3---figure supplement 3.Label-free MS1 analysis of synthetic SOX2 TAD peptides.The WT unmodified (grey), WT *O*-GlcNAc modified (red) and S248A unmodified peptides (blue) were loaded at known concentrations and the MS1 peak area was plotted.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.017](10.7554/eLife.10647.017)

LC-MS/MS analysis of immunopurified SOX2 from fSOX2-Tg mESCs identified nine PTM forms of the SOX2 TAD peptide ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). LC-MS analysis of the TAD peptide precursor masses from fSOX2-Tg mESCs showed unmodified and singly *O*-GlcNAcylated were the most abundant forms of the SOX2 TAD peptide (33.2 and 44.1% of total TAD, respectively) ([Figure 3D](#fig3){ref-type="fig"}). LC-MS analysis confirmed the loss of S248 *O*-GlcNAcylation in fS248A-Tg mESCs ([Figure 3E](#fig3){ref-type="fig"}). Analysis of synthetic SOX2 TAD peptides showed chromatographic separation of PTM or mutant isoforms, and lack of electrospray ionization suppression, validating our label free quantitation approach ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). In addition, the TAD peptide in fS248A-Tg mESCs showed increased phosphorylation at S253, from 10.9 to 18.7% of total TAD, suggesting cross talk between phosphorylation and *O*-GlcNAcylation.

SOX2^S248A^ alters gene expression in mESCs {#s2-4}
-------------------------------------------

To determine if the S248A mutation altered global transcript levels we used microarrays to compare the gene expression profiles of fSOX2-Tg and fS248A-Tg mESCs. Significant changes in mRNA levels were observed, with 320 genes up regulated and 344 genes down regulated in fS248A-Tg cells ([Figure 4A](#fig4){ref-type="fig"}) and gene set enrichment analysis of differentially expressed genes did not show significant enrichment of any pathways. Several genes that promote pluripotency and self-renewal were upregulated, while several genes associated with differentiation were down-regulated in fS248A-Tg cells compared to WT. RT-qPCR confirmed the differential expression of these pluripotency or differentiation genes ([Figure 4B](#fig4){ref-type="fig"}). These data suggest the S248A mutation alters the balance between self-renewal and differentiation gene expression in mESCs.10.7554/eLife.10647.018Figure 4.fS248A-Tg mESCs show altered gene expression and decreased dependence on OCT4.(**A**) Volcano plot of global changes in gene expression between fSOX2-Tg and fS248A-Tg cells. Red indicates genes with increased or decreased expression (fold change cutoff 1.5 and paired t-test p\<0.05) ([Supplementary file 1a](#SD1-data){ref-type="supplementary-material"}). (**B**) RT-qPCR of select genes differentially expressed between fSOX2-Tg and fS248A-Tg cells (\* indicates p\<0.05, n=3, +/- S.E.M.). (**C**) fSOX2-Tg or fS248A-Tg cells were depleted of OCT4 using siRNA pools (esiRNAs) and Western blot analysis of OCT4 and TUBULIN were performed. (**D**) and (**E**), (**D**) AP staining and (**E**) quantitation of fold change in AP staining three days after OCT4 or GFP depletion in fSOX2-Tg and fS248A-Tg cells. Additional example fields of view for relative quantitation can be seen in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. F, RT-qPCR analysis of *Oct4* and *Nanog* mRNA levels in fSOX2-Tg or fS248A-Tg cells depleted of OCT4 compared to the control knockdown of GFP.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.018](10.7554/eLife.10647.018)10.7554/eLife.10647.019Figure 4---figure supplement 1.AP activity staining of fSOX2-Tg and fS248A-Tg cells three days after *Gfp* or *Oct4* knockdown.Four fields of view, shown here, were used for relative AP stain quantitation for a representative replicate. Mock knockdown (*Gfp*) was used as the baseline for AP staining.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.019](10.7554/eLife.10647.019)

The altered gene expression profile of fS248A-Tg cells suggested this mutation may promote self-renewal at the expense of differentiation. Therefore, we examined the effects of OCT4 depletion, which causes mESCs to differentiate ([Figure 4C](#fig4){ref-type="fig"}) ([@bib19]). While fSOX2-Tg mESCs exhibited altered cell and colony morphology ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), decreased AP staining ([Figure 4D](#fig4){ref-type="fig"}), and decreased expression of *Nanog* ([Figure 4E](#fig4){ref-type="fig"}), fS248A-Tg mESCs were relatively unaffected by OCT4 depletion. These data indicate that fS248A-Tg mESCs can maintain key features of pluripotency when OCT4 levels are reduced, and are consistent with a role for the *O*-GlcNAc modification inhibiting SOX2 activity.

SOX2^S248A^ exhibits altered genomic occupancy {#s2-5}
----------------------------------------------

To examine whether the altered gene expression associated with the S248A mutation was accompanied by changes in SOX2 genomic occupancy, we performed FLAG chromatin immunoprecipitation followed by next generation sequencing (ChIP-seq) to compare SOX2 genomic distribution in fSOX2-Tg and fS248A-Tg mESCs ([Figure 5A](#fig5){ref-type="fig"}). SOX2 distribution exhibited considerable overlap, with 4,191 sites bound in both lines ([Figure 5B](#fig5){ref-type="fig"}). The mutant form of SOX2 occupied 1000 sites not bound by the wild type form ([Figure 5A](#fig5){ref-type="fig"}). *De novo* motif analysis identified the SOX2 binding motif in fS248A-Tg specific peaks ([Figure 5C](#fig5){ref-type="fig"}). In mESCs, SOX2 and OCT4 heterodimerize and co-occupy a substantial portion of their target regulatory sequences ([@bib6]). *De novo* motif analysis of SOX2 peaks shared between fSOX2-Tg and fS248A-Tg mESCs identified the OCT4:SOX2 motif ([Figure 5D](#fig5){ref-type="fig"}), which was present in 2335 of the shared peaks. The OCT4:SOX2 motif was not identified in any of the fS248A-Tg-specific peaks ([Figure 5E](#fig5){ref-type="fig"}). These data indicate the S248A mutation alters SOX2 genomic distribution, increasing its ability to associate with SOX2 binding sites that would not ordinarily be bound by wild type SOX2 in mESCs.10.7554/eLife.10647.020Figure 5.S248A mutation alters genome-wide distribution of SOX2.(**A**) Representative UCSC genome browser tracks of FLAG ChIP-seq in fSOX2-Tg (blue) and fS248A-Tg (red) cells. Examples of fS248A-Tg specific peaks (*Pou5f1, Esrrb*) and shared peaks (*Abca4, Sox2*) are shown for 2 biological replicates (2 technical replicates were performed for each biological replicate, Spearman correlations for technical replicates are 1, for biological replicates 0.45 for fSOX2-Tg and 0.55 for fS248A-Tg). Each track is 15 kb. Green arrows indicate fS248A-Tg specific peaks. For *Sox2* track, the region shown is not encompassed in the deletion removing endogenous *Sox2*. (**B**) Overlap (purple) in called peaks from anti-FLAG ChIP-seq in fSOX2-Tg (blue) and fS248A-Tg (red) mESCs. (**C**) *De novo* SOX2 motif identified in shared ChIP-seq peaks between fSOX2-Tg and fS248A-Tg cells (top) compared to the canonical SOX2 motif \[Jaspar M01271\] (bottom). (**D**) OCT4:SOX2 motif identified in peaks shared between fSOX2-Tg and fS248A-Tg cells using *de novo* motif analysis (top) compared to the canonical OCT4:SOX2 motif \[Jaspar MA0142.1\] (bottom). (**E**) Proportion of peaks containing a motif matching the OCT4:SOX2 *de novo* motif in shared peaks (left) and fS248A-Tg specific peaks (right).**DOI:** [http://dx.doi.org/10.7554/eLife.10647.020](10.7554/eLife.10647.020)

*O*-GlcNAc alters SOX2 protein-protein interactions {#s2-6}
---------------------------------------------------

S248 lies in the TAD of SOX2, a region responsible for interactions with transcriptional regulatory machinery ([@bib1]; [@bib27]; [@bib42]). Therefore, we tested whether the S248A mutation altered SOX2 centered protein-protein interactions (PPIs). We performed affinity purifications against FLAG from nuclear extracts of fSOX2-Tg, fS248A-Tg or an equivalent mESC line expressing transgenic HA-tagged SOX2 (haSOX2-Tg, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) and used quantitative LC-MS to identify proteins that co-purified with FLAG in each cell type. We identified 329 proteins enriched in both fSOX2-Tg and fS248A-Tg, but not haSOX2-Tg FLAG IPs. Many of these interactors exist in complexes involved in histone modification, DNA damage repair, or nucleosome remodeling ([Figure 6A](#fig6){ref-type="fig"}). Several SOX2 interactors have been previously described ([@bib9]; [@bib11]; [@bib16]), indicating fSOX2-Tg and fS248A-Tg cells recapitulate some known SOX2 interactions ([Supplementary file 1b](#SD1-data){ref-type="supplementary-material"}).10.7554/eLife.10647.021Figure 6.*O*-GlcNAcylation of SOX2 at S248 alters protein-protein interactions.(**A**) Interaction diagram of a subset of SOX2 interactors that exhibit differential association with 3xF-SOX2^S248A^ relative to 3xF- SOX2^WT^. Color of circles indicates with which SOX2 proteoform a protein preferentially interacts. Interaction diagram based on high confidence, experimental interactions identified by STRING. (**B**), Anti-FLAG IP-WB for SOX2, PARP1, GATAD2B, and SMARCA4 in fSOX2-Tg and fS248A-Tg cells. (**C**) Heatmap of median enrichment values of NuRD subunits that preferentially associate with 3xF-SOX2^WT^ or 3xF-SOX2^S248A^ as determined by quantitative mass spectrometry (n=3). (**D**) Western blot analysis of in vitro interaction between SOX2 +/- *O*-GlcNAcylation and PARP1. Bio-SOX2 and His-OGT were incubated with and without UDP-GlcNAc, Bio-SOX2 purified away from OGT and UDP-GlcNAc using streptavidin beads and incubated with GST-PARP1. Western blots examine proteins associated with streptavidin beads. Comparable amounts of input and pull down were loaded for all blots, except *O*-GlcNAc, in which more material was loaded in the pull down lanes. WB, Western blot; GST, glutathione S-transferase tag; Bio, biotinylated Bio tag; His, polyhistidine tag. (**E**) Flow chart outlining scheme for **D**.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.021](10.7554/eLife.10647.021)10.7554/eLife.10647.022Figure 6---figure supplement 1.Creation of haSOX2-Tg, where HA-tagged SOX2 is the sole source of SOX2.Western blots compare parental line to haSOX2-Tg ESCs. Below table shows MS analysis identifies GlcNAc-S248 in these cells.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.022](10.7554/eLife.10647.022)10.7554/eLife.10647.023Figure 6---figure supplement 2.*O*-GlcNAc site mapping by ETD-MS/MS of recombinant Bio-tagged human SOX2 incubated with recombinant human OGT and UDP-GlcNAc.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.023](10.7554/eLife.10647.023)

We next examined whether any co-purifying proteins were enriched in either the fSOX2-Tg or fS248A-Tg co-IPs, by plotting the enrichment ratios between S248A and wild type. 22 of the interacting proteins were enriched at least four-fold in the co-IP with fSOX2-Tg (z-score \> 1.5) and 60 were enriched in the fS248A-Tg co-IP ([Supplementary file 1b](#SD1-data){ref-type="supplementary-material"}). Co-IP followed by Western blotting corroborated the IP-MS data, showing preferential enrichment of PARP1 and GATAD2B with mutant and wild type SOX2, respectively, while SMARCA4 was associated equally with both forms of SOX2 ([Figure 6B](#fig6){ref-type="fig"}).

Examination of the protein complexes enriched by either wild type or S248A SOX2 showed a subset of components behaved discordantly with the rest of the complex subunits. For example, MBD3 and MTA3, both of which can be a part of the NuRD complex, were consistently enriched in fS248A-Tg co-IPs while other NuRD components were enriched with fSOX2-Tg ([Figure 6B](#fig6){ref-type="fig"}). To more thoroughly investigate the subunit distribution of a subset of the NuRD complex, we used a targeted proteomic approach based on interacting proteins from an MBD3 co-IP experiment. We performed anti-FLAG affinity purifications in FLAG tagged MBD3 mESCs ([@bib41]) followed by LC-MS to generate a representative set of NuRD complex peptides. The top two, best scoring, unique peptides for each NuRD component were used to determine the relative enrichment of these proteins from fSOX2-Tg and fS248A-Tg co-IPs ([Supplementary file 1c](#SD1-data){ref-type="supplementary-material"}). Targeted analysis showed the majority of the NuRD complex preferentially associated with SOX2^WT^, while MBD3 and MTA3 components prefer SOX2^S248A^ ([Figure 6C](#fig6){ref-type="fig"}). These results suggest that the S248A mutation can affect the stoichiometry of subunits in complexes that associate with SOX2.

The altered PPIs with SOX2^S248A^ may occur as a direct result of the lack of *O*-GlcNAcylation of S248. To test whether the *O*-GlcNAcylation of SOX2 was directly responsible for alterations in a PPI, we used recombinant proteins to assess the effect of this PTM on the SOX2-PARP1 interaction. *O*-GlcNAcylation of Bio-tagged, recombinant human SOX2 (Bio-SOX2, 96% identical to mouse) by recombinant human OGT (His-OGT, 99% identical to mouse), which depended on the sugar donor UDP-GlcNAc, was detected by Western blotting ([Figure 6D](#fig6){ref-type="fig"}) and specificity confirmed by mass spec ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Bio-SOX2 was bound to streptavidin magnetic beads to remove OGT and UDP-GlcNAc. Beads bound by *O*-GlcNAcylated or unmodified SOX2 were incubated with GST-tagged, recombinant human PARP1 (GST-PARP1, 91% identical to mouse) ([Figure 6E](#fig6){ref-type="fig"}). Pull down efficiency of Bio-SOX2 was not affected by *O*-GlcNAcylation and His-OGT was not detected in pull downs, indicating any potential SOX2:OGT interaction was not stable under our wash conditions. Unmodified Bio-SOX2 pulled down GST-PARP1, indicating the interaction between mouse SOX2 and PARP1 can be recapitulated by their conserved human homologues. Pulldown efficiency of GST-PARP1 by glycosylated Bio-SOX2 was diminished compared to that of unmodified Bio-SOX2 ([Figure 6D](#fig6){ref-type="fig"}). Together, these data demonstrate SOX2 *O*-GlcNAcylation directly alters its interaction with a transcriptional regulatory protein involved in maintaining the balance of self-renewal and differentiation ([Figure 7](#fig7){ref-type="fig"}).10.7554/eLife.10647.024Figure 7.Model for the role of *O*-GlcNAcylation in regulation of SOX2 in mESCs.(**A**) *O*-GlcNAc (sugar moiety) affects the affinity of SOX2 (red) for interacting proteins (ovals). Some proteins (blue shapes) exhibit greater affinity for unmodified SOX2, while others exhibit lower affinity (orange shapes). In addition, *O*-GlcNAcylation affects SOX2 binding to a subset of target DNA sequences. (**B**) As a result of altered genomic distribution and protein-protein interactions when SOX2 cannot be *O*-GlcNAcylated (SOX2^S248A^), pluripotency gene expression is promoted at the expense of differentiation.**DOI:** [http://dx.doi.org/10.7554/eLife.10647.024](10.7554/eLife.10647.024)

Discussion {#s3}
==========

Depletion of OGT, the sole enzyme that mediates intracellular *O*-GlcNAcylation, disrupts mESC self-renewal ([@bib28]; [@bib33]), prompting us to identify OGT targets to elucidate link between *O*-GlcNAc and self-renewal. Using an unbiased strategy for enrichment of native *O*-GlcNAcylated nuclear peptides, we previously identified SOX2 S248 as an OGT substrate ([@bib26]). Here, we find that S248 is *O*-GlcNAcylated during somatic cell reprogramming and that mutation of this residue to alanine increases reprogramming efficiency. We also find mESCs expressing SOX2^S248A^ exhibit changes in transcription consistent with increased expression of pluripotency promoting genes at the expense of differentiation promoting genes. Together, these analyses from both mESCs and during somatic cell reprogramming reveal the S248A mutation promotes SOX2 activity, which suggests SOX2 *O*-GlcNAcylation is inhibitory during maintenance and establishment of pluripotency.

Our data indicate that S248 *O*-GlcNAcylation is regulated by developmental signaling molecules, since removing LIF and adding RA to trigger differentiation resulted in a substantial decrease in this PTM. This decrease in S248 *O*-GlcNAcylation appears contradictory to the finding that the S248A mutation, which eliminates *O*-GlcNAcylation, promotes mESC self-renewal. However, the effects of this, or any, PTM are likely to be context specific, and determined by the transcription factors and signaling molecules present in each cell type. GlcNAc-S248 may inhibit SOX2 activity in mESCs, where the decrease in this PTM may alter SOX2 activity upon differentiation, such that SOX2 functions appropriately for the changing cellular context. As this work shows, use of methods that allow analysis of SOX2 PTM-specific PPIs and genomic occupancy may be crucial to understand how combinations of PTMs are used to regulate SOX2 activity in response to developmental cues.

In addition to changes in gene expression, the S248A mutation altered SOX2 genomic distribution. As well as occupying the same sites as SOX2^WT^, SOX2^S248A^ was found at an additional 1000 sites. The majority of these sites contained a predicted SOX2 binding motif, indicating the mutation allows SOX2^S248A^ to occupy sites that SOX2^WT^ is unable to access in mESCs. This result suggests *O*-GlcNAcylation can regulate the affinity of SOX2 for its target sites. Since the mutation lies in the TAD, but affects the activity of the high mobility group DNA binding region, the mutation or loss of *O*-GlcNAcylation could affect secondary protein structure and/or PPIs. Single molecule imaging of SOX2 with a deleted TAD showed altered DNA occupancy and higher site-specific residence time, supporting the idea that TAD mutations affect SOX2 DNA binding ([@bib8]).

Upon OCT4 knockdown, fS248A-Tg mESCs did not exhibit as dramatic a change in colony morphology as fSOX2-Tg mESCs. In addition, the new sites of genomic occupancy seen in fS248A-Tg mESCs did not have nearby predicted OCT4 motifs. Together these results suggest the *O*-GlcNAc-deficient SOX2 may exhibit an altered reliance on OCT4 for binding and regulation of gene expression. Further studies aimed at querying the effects of the S248A mutation on genome-wide OCT4 distribution should provide insight into whether this SOX2 PTM alters OCT4 association with target sequences, and may address if *O*-GlcNAc impacts OCT4/SOX2 heterodimerization.

Our proteomic analyses indicated there are substantial differences in SOX2-centered PPIs in fS248A-Tg mESCs. Many of the proteins that exhibited differential interaction between wild type and mutant SOX2 are components of complexes implicated in chromatin regulation. These altered associations may underlie the transcriptional and genomic occupancy changes seen in the mutant mESCs. In addition, components of the PARP-XRCC and the DNA mismatch repair (MMR) complexes were enriched with SOX2^S248A^, suggesting the possibility that these complexes may function in transcriptional regulation in addition to DNA repair. Consistent with this hypothesis, DNA damage complexes promote mESC self-renewal and iPSC generation ([@bib14]).

Our PARP1 results are consistent with previous reports describing its interaction with SOX2 in mESCs ([@bib15]; [@bib23]). In both these studies, differentiation of mESCs promotes the PARP1-SOX2 interaction. We found PARP1 interaction with SOX2 is disrupted by *O*-GlcNAc and decreased GlcNAc-S248 in differentiating ESCs, consistent with a model in which the developmentally regulated decrease in S248 *O*-GlcNAcylation promotes PARP1 interaction. During differentiation, the SOX2-PARP1 interaction inhibits SOX2 binding to enhancers of genes that are necessary for self-renewal ([@bib23]). We find that SOX2^S248A^ exhibits increased association with PARP1 without decreased occupancy of pluripotency genes under self-renewal conditions. This result indicates the SOX2-PARP1 interaction alone does not inhibit SOX2 binding to pluripotency gene targets and suggests additional developmentally regulated alterations in SOX2 PTMs or interaction partners contribute to control of SOX2 occupancy.

The increase in SOX2 S253 phosphorylation in fS248A-Tg mESCs suggests there is potential for crosstalk between *O*-GlcNAcylation and phosphorylation in the TAD peptide in mESCs. In general, phosphorylation and *O*-GlcNAcylation both occur in structurally flexible regions of proteins, although there is no correlation or anti-correlation in the linear proximity of one PTM to another ([@bib37]). It is unlikely phospho-S253 has a substantial impact on pluripotency gene expression, as S253 phosphorylation is dispensable for mESC self-renewal ([@bib30]). However, because the TAD of SOX2 is an unstructured domain ([@bib32]), and is *O-*GlcNAcylated and phosphorylated, the molecular basis for the potential crosstalk may be specific to a different cellular context.

*O*-GlcNAc signaling is essential for pluripotency. However, reliable *O-*GlcNAc site identification, as well as investigation into this PTM's function, is in their infancy. This study shows that although global *O-*GlcNAcylation is necessary for mESC self-renewal, a key pillar of pluripotency can be inhibited by *O-*GlcNAc modification. This work provides a new mechanism for the regulation of SOX2 through *O-*GlcNAcylation, and illustrates the role of this PTM in pluripotency and self-renewal is more complex than previously appreciated.

Materials and methods {#s4}
=====================

Cell line derivation {#s4-1}
--------------------

2TS22C mESCs (accession number AES0125), the parental cell line for derivation of tagged SOX2 lines ([@bib25]), were obtained through Riken BioResource Center. Identity of this line, which contains a SOX2 transgene under control of a tet-repressible promoter, was authenticated by culturing cells with and without doxycycline and examining SOX2 expression by Western blotting. To create the fSOX2-Tg ESC line, 4 ug of the plasmid CAG-3xF-Sox2 was transfected with Lipofectamine 2000 (Thermo Fisher \[Invitrogen\], Waltham, MA) into a 6-well plate containing 2TS22C cells. 2TS22C mouse ESCs express SOX2 under control of a tetracycline-repressible system. Twenty-four hours after transfection 1 ug/mL doxycycline was added to silence expression of the TetO Sox*2*. Forty-eight hours after transfection, 7 ug/mL puromycin was added, to select for the integration and expression of CAG-3xF-Sox2. After about two weeks, colonies exhibiting the typical ESC morphology were expanded and tested via western blot, morphology and alkaline phosphatase staining (Clontech, Mountain View, CA). The same strategy was used to generate the fS248A-Tg and haSOX2-Tg ESC lines.

Cell culture {#s4-2}
------------

Mouse ESC lines were routinely passaged by standard methods in ESC media (KO-DMEM, 10% FBS, 2 mM glutamine, 1X non-essential amino acids, 1x pencillin/streptomycin, 0.1 mM b-mercaptoethanol and recombinant leukemia inhibitory factor). 2TS22C, fSOX2-Tg, fS248A-Tg, and haSOX2-Tg ESCs were cultured in ESC media with 1 ug/mL doxycycline hyclate (Sigma). KI mESCs ([@bib23]) were cultured in N2B27 plus 2i (Thermo Fisher \[Life Technologies\], Waltham, MA) and LIF or 500 uM retinoic acid (Sigma-Aldrich, St.Louis, MO). Mycoplasma testing was carried out every two months until the cells were found to be negative for several successive tests.

Plasmids {#s4-3}
--------

CAG-3xF-Sox2 was constructed by inserting mouse Sox2 cDNA into pCMV-3xFLAG 7.1 (Sigma-Aldrich) and then subcloning 3xF-Sox2 via InFusion cloning (Clonetech) into CAG-HA-Sox2-IP (Addgene plasmid 13459), replacing the HA tag with the triply FLAG tagged. S248A mutations in CAG-3xF-Sox2 were performed with Quickchange site directed mutagenesis (Agilent Technologies \[Stratagene\], Santa Clara, CA) (Supp Table S4). pMXs-mouse Sox2 wild type or S248A, along with pMXs-Oct4, Klf4 and c-Myc were used ([@bib29]; [@bib36]). The pMXs-3xF-Sox2 was created by cloning Sox2 into pCMV-3xFLAG 7.1 (Sigma-Aldrich) and then subcloning 3xF-Sox2 via InFusion cloning (Clonetech) into pMXs.

Antibodies and alkaline phosphatase {#s4-4}
-----------------------------------

Antibodies were purchased from:

Abcam, United Kingdom: SOX2 ab75179 (immunofluorescence \[IF\] and in vitro assay WB, TUBULIN GTU-88 ab11316 (Western blot \[WB\]), HA ab13834 (WB, IP), OCT4 ab19857 (IF)

Reprocell USA INC, Boston, MA: NANOG, RCAB002P-F (IF)

SIGMA-Aldrich: OGT DM-17 (WB), FLAG A8592 (WB), FLAG F1804 (IF and ChIP)

Santa Cruz Biotechnology Inc, Santa Cruz, CA: OGT SC32921 (in vitro assay WB), OCT4 SC8628x(WB)

Bethyl Laboratories, Inc, Montgomery, TX: SMARCA4 A300-813A (WB), PARP1 A301-375A (WB), GATAD2B 301-281A (WB)

Pierce/ThermoFisher: O-GlcNAc MA1072 (WB)

ActiveMotif, Carlsbad, CA: PARP1 39,559 (in vitro assay WB)

Bio-Rad Laboratories, Inc, Hercules, CA: goat anti-rabbit HRP conjugate 172--1019 and goat anti-mouse HRP conjugate 172--1011 (WB)

Jackson Laboratory, Bar Harbor, ME: Alexa Fluor 488-donkey anti-rabbit IgG 711-545-152 (IF)

Alkaline phosphatase activity staining was performed according to manufacturer\'s instructions (Stemgent, Cambridge, MA, 00--0055).

SOX2 purification for PTM characterization {#s4-5}
------------------------------------------

KI mESCs, fSOX2-Tg or fS248A-Tg cells were expanded to one to three 15 cm^2^ dishes depending on the experiment. Cells were harvested by trypsinization, washed once with cold PBS and frozen in liquid nitrogen. Whole cell pellets were lysed in RIPA buffer without SDS, containing 500 nM Thiamet G (Caymen Chemicals, Ann Arbor, MI), 1X HALT protease and phosphatase inhibitors (Thermo Fisher\[Pierce\]), 2 mM TCEP (Sigma) and 20 mM *N-*ethylmaleimide (Sigma-Aldrich) and sonicated (with a probe sonicator on methanol ice for three rounds of pulses, 3 s on, 2 off, 10 s total, at 35%). Anti-FLAG-based purifications were performed with anti-FLAG M2 Dynabeads (Sigma-Aldrich, M8823). Whole cell lysates were incubated with M2 beads at room temperature for 75 min, washed once with lysis buffer and three times with 25 mM ammonium bicarbonate (ABC) with 150 mM NaCl. Proteins were eluted with 100 mM glycine pH 4 for five minutes. Western blot and SDS-PAGE analysis was used to assess purification efficiency. For HA-SOX2 purification, anti-HA antibodies were coupled to aldehyde-coated magnetic beads (BioClone, San Diego, CA) via reductive amination in 20 mM bicine pH 7.8 and purified as above. Two 10 cm^2^ dishes of CD1 MEFs infected with OS^FLAG-WT^KM or OS^FLAG-S248A^KM for six days were analyzed the same way.

Mass spectrometric analysis of SOX2 PTMs {#s4-6}
----------------------------------------

Silver or Coomassie stained SDS-PAGE gel bands were excised and digested in-gel with sequence grade trypsin (Roche, Switzerland). After 5% formic acid/50% acetonitrile extraction, peptides were dried by vacuum centrifugation, gel particulates were removed via C18 Zip Tips (MERCK Millipore, Billercia, MA), dried, resuspended in 0.1% formic acid and analyzed by LC-MS/MS. Chromatography was performed on a Nanoacquity HPLC (Waters, Milford, MA) at 400 nl/min with a BEH130 C18 2.1x150 mm column (Waters). A 90- or 120-minute gradient from 98% solvent A (0.1% formic acid) to 22% solvent B (0.1% formic acid in acetonitrile) was used. Peptides were analyzed by an LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific, Waltham, MA). After the survey scan of m/z 400--1,600 was measured in the Orbitrap at 30,000 resolution, the top three multiply charged ions were selected for both HCD and ETD. Automatic gain control for MS/MS was set to 2000. Normalized collision energy for HCD was set at 35 while the ETD activation time was charge state dependent, based on 100 ms for doubly charge precursors. Supplemental activation was implemented for ETD reactions. Dynamic exclusion of precursor selection was set for 25 s.

WT GlcNAc-S248, WT unmodified and the S248A SOX2 TAD were synthesized by New England Peptide and analyzed as described above.

Data analysis {#s4-7}
-------------

Fragment mass spectra were converted into peaklists using the in-house software PAVA. HCD and ETD data were searched separately using ProteinProspector version 5.10.0 against the UniProt database with a concatenated database. Only mouse and human genomes were used for the database searching. Precursor tolerance was set to 10 ppm, whereas fragment mass error tolerance was set to 0.6 Da for ETD and 20 ppm for HCD. N-terminal acetylation, methionine oxidation, loss of N-terminal methionine and glutamate conversion to pyroglutamate were allowed as variable modifications. For ETD data, HexNAc modifications to serine and threonine residues and phosphorylation to serine/threonine/tyrosine was allowed as variable mass modifications. For HCD, phosphorylation was searched the same way though HexNAc was considered as a neutral loss. Methylation (mono, di- and tri-) of K and R, monomethylation of D, E and H (artifact from MeOH fixing PAGE gels), acetylation of K and R, and ADP-ribosylation to C, E, K, N, S, and R were searched separately. SLIP scoring was used to distinguish possible positional isomers of HexNAc and/or phosphopeptides ([@bib4]). Relative abundances of each modified or unmodified peptide were calculated using the ICIS area calculated from XICs in Xcalibur (Thermo Scientific) at a 10 ppm mass tolerance.

Analysis of 3xF-SOX2 interactors {#s4-8}
--------------------------------

Six to ten 10 cm^2^ plates worth of haSOX2-Tg, fSOX2-Tg or fS248A-Tg cells were harvested for nuclear extract preparations in biological duplicate. Nuclear extracts were as previously described with minor modifications ([@bib10]). Buffers A, C and D were supplemented with 2 µM Thiamet G, 2 µM PUGNAc (Tocris Bioscience, United Kingdom) and 1X HALT protease and phosphatase inhibitors and instead of dialysis of extracts, two volumes of buffer D were used to dilute salt concentration. Seven µL of M2 beads per 10 cm^2^ plate were used per co-IP and samples were nutated at 4^o^C for two hours. Beads were washed once with Buffer D plus inhibitors, then twice with 50 mM ABC with 150 mM NaCl. Each wash was only as long as it took to transfer the beads to a new, cold tube and place on the magnetic rack. Beads were then resuspended in 50 µL 100 mM ABC with 500 ng trypsin and shaken at 37^o^C for one hour. Supernatant was transferred to a new tube, the beads were washed once with 50 µL ABC and combined to digest overnight. Digestions were desalted with one or two Zip Tips, depending on size of experiment, and dried via vacuum centrifugation. IP-WB experiments were performed similarly except proteins were eluted with 2X SDS-PAGE loading buffer without reducing agent.

Chromatography was performed on a Nanoacquity HPLC (Waters) at 400 nl/min with an EASY-spray 15 cm x 75 µm ID, PepMap C18, 3 µm column (Thermo Scientific). A 90-minute gradient from 98% solvent A (0.1% formic acid) to 22% solvent B (0.1% formic acid in acetonitrile) was used. Peptides were analyzed on a Q-Exactive Plus mass spectrometer (Thermo Scientific). After the survey scan of m/z 400--1,600 was measured in the Orbitrap at 70,000 resolution, the top ten multiply charged ions were selected for HCD and measured at 17,500 resolution. Normalized collision energy for HCD was set at 35, Dynamic exclusion of precursor selection was set for 25 s.

The label-free quantiation (LFQ) feature of MaxQuant (1.5.1.0) was used to quantify protein signals for proteins identified in the co-IP experiments. For SOX2, only non-TAD peptides were used for protein level quantitation. Proteins were determined to be SOX2 interactors by taking the average ratio of the LFQ intensity of the protein of interest (POI) from the FLAG-tagged mESC lines over the HA-tagged mEScs. This average ratio was log~2~-transformed, and was normalized by the global median. If the POI was two standard deviations from the mean it was considered specific to SOX2. Most proteins discussed were manually verified using Skyline.

To determine POIs that differentially interact with wild type or S248A SOX2, we took the ratio of the log~2~-transformed ratio of FLAG/HA for S248A over the wild type. After normalization by the global median, POIs were considered to be differential interactors if they had a z-score of greater than 1.5. All of these peptides were manually verified using Skyline.

For targeted analyses, FLAG-tagged MBD3 mESCs, a generous gift from the Fazzio laboratory ([@bib41]) were analyzed as described above. From these analyses the top two most intense, non-homologous peptides identified from NuRD subunits were used to monitor their co-purification with SOX2 isoforms in fSOX2-Tg and fS248A-Tg cells in three separate, biological replicates. XICs were extracted manually using Xcalibur software. Relative enrichment of proteins co-purified with either SOX2 form was determined as described above. Peptides used for this analysis are listed in Supplementary Table 1b.

Samples for co-IP Western blot corroboration of LC-MS data were performed as described above in biological duplicate. Antibodies used are described above.

Reprogramming experiments {#s4-9}
-------------------------

MEFs were derived from wild type CD1 mice or the Nanog-Gfp-IRES-Puror mice ([@bib29]) and cultured in MEF media (KO-DMEM, 10% FBS, 2 mM glutamine, 1X non-essential amino acids, 1X pencillin/streptomycin, and 0.1 mM β-mercaptoethanol). pMXs vectors containing *Oct4, c-Myc, Klf4, eGfp, dsRed*, or wild type or S248A *Sox2*, with or without FLAG, were transfected with Fugene 6 (Promega, Madison, WI, E2691) into PlatE cells. Twenty-four hours after transfection, the media was changed. The next day, the retroviral supernatant was collected from transfected PlatE cells, filtered through 0.4 um filters and combined with each other at equal ratios. Polybrene (Merck Millipore, TR-1003-G) was added to a final concentration of 4 ug/ml. The virus-containing media was added to *Nanog-Gfp* or wild type MEFs that were passaged less than five times. Media was replaced the next day and every other until six days after transduction. At day six, MEFs were trypsinized and either prepared for experiments or 1000 cells were plated onto γ-irradiated SNL feeders. These 1000 MEFs were cultured in ESC media until GFP+ colonies were counted at day 20 (*Nanog-Gfp* MEFs).

Microinjection of iPSCs to generate chimera mice was conducted at Cornell University Stem Cell and transgenic core facility. iPSCs were grown on mouse embryonic fibroblasts (produced at the Cornell stem cell core) and mitotically inactivated by irradiation (3000 Rads). To produce donor embryos, wild type albino mice of the strain <http://jaxmice.jax.org/strain/000058.html> were mated, embryos were flushed from the uterus at day 3.5, and the iPSCs were injected into the blastocyst of each embryo (15--30 cells per embryo). Injected embryos were then transferred to 2.5-day pseudo pregnant recipient animals and pup chimaerism was determined by coat color. Chimeras were mated to age-matched wild type animals of the same albino strain used for embryo donors. iPSC contribution to the germline was determined by coat color of the resultant pups.

Microarray analysis {#s4-10}
-------------------

Total RNA was extracted with Trizol (Thermo Fisher \[Invitrogen\]) according to manufacturer's instructions. Arraystar Inc, Rockville, MD(<http://www.arraystar.com>) prepped and hybridized the samples, and performed the data analysis.

For RT-qPCR, 1 µg total RNA was reverse transcribed to cDNA with iScript (Bio-Rad Laboratories), diluted 1:20 or 1:50, depending on the abundance of the transcript, and 4 µL was used. Quantitative PCR was performed on a CFX Connect Real-time PCR detection system (Bio-Rad laboratories) with SensiFast SYBR Lo-ROX PCR master mix (Bioline, Taunton, MA, BIO-94020). Fold enrichment was determined by 2^-(ΔCq)^ method (ΔCq= Cq(gene)-Cq(*GusB*)). Primers are listed in [Supplementary file 1d](#SD1-data){ref-type="supplementary-material"}.

Recombinant SOX2-OGT reaction and GST-PARP1 pulldown {#s4-11}
----------------------------------------------------

The recombinant poly-His tagged human OGT (His-OGT) expression plasmid was a generous gift from Suzanne Walker. His-OGT was expressed as previously described ([@bib17]). His-OGT was purified by Ni-NTA agarose resin (Qiagen, Germany), eluted and buffer exchanged into 50 mM Tris-HCl, pH 7.8, 300 mM NaCl. To generate a biotinylated SOX2 (Bio-SOX2), the human SOX2 cDNA was cloned into the expression vector, pGV358avi, as a fusion construct linked to an N-terminal Avi-tag and a C-terminal intein-chitin binding domain ([@bib31]). Bio-SOX2 was produced in E.coli BL21(DE3) in media supplemented with 200 nM biotin. The protein was purified from a clarified lysate by passage over a chitin column (New England Biolabs (NEB), Ipswich,MA) and incubated overnight in buffer containing 20 mM Tris-HCl, pH 8.5, 500 mM NaCl, 1 mM EDTA, 10% glycerol and 50 mM DTT. Bio-SOX2 was then eluted from the chitin column and dialyzed into storage buffer (20 mM Tris-HCl,pH 8.5, 500 mM NaCl, 1 mM EDTA, 10% glycerol and 1 mM DTT) for long term storage at -80^o^C.

Equimolar ratios of Bio-SOX2 and His-OGT were incubated in an *O*-GlcNAc assay buffer (50 mM Tris pH 7.4, 12.5 mM MgCl~2~, 2% glycerol, 0.2 mM PMSF, 1 mM DTT) for one hour at 37^o^C with or without the sugar donor, UDP-GlcNAc (100 µM). After one hour, 50 µl of streptavidin magnetic beads (Thermo Fisher, 11205D) were resuspended in PBS/BSA(0.1%) buffer were added and the reactions were incubated for 45 min at 4^o^C. Bio-SOX2 bound beads were washed twice with PBS/BSA, once with low salt buffer (PBS/BSA+150 mM NaCl) and once with high salt buffer (PBS/BSA+300 mM NaCl) to eliminate His-OGT and unincorporated UDP-GlcNAc. Finally, the beads were resuspended in 50 µl of PBS/BSA buffer and incubated at 4^o^C for 1 hr with recombinant GST-PARP1 protein (0.14 µM) (Sigma-Aldrich, SRP0192). The beads were washed three times in PBS/BSA buffer and eluted in 1X SDS-PAGE loading buffer. Pull down and input samples were resolved on a 10% SDS-PAGE gel and Western blotted for SOX2, (Abcam, ab75179), OGT (SantaCruz Biotechnology Inc,SC 32921) *O*-GlcNAc (Thermo Fisher \[Pierce, MA1072) and PARP1 (Active Motif, AM 39559).

Knockdown {#s4-12}
---------

siRNA pools (esiRNAs) were created by in vitro cleavage of double-stranded RNA ([@bib13]). In vitro transcription templates for double stranded RNAs were generated using the primers acquired from the Riddle database ([@bib21]). Transfections were performed using Lipofectamine RNAiMax according to manufacturer\'s instructions.

ChIP sample preparation {#s4-13}
-----------------------

The cells from ∼80% confluent 10 cm^2^ dishes were crosslinked with 1% formaldehyde for 10 min at room temperature. After quenching with 125 mM glycine for 5 min, the cells were washed twice with ice cold PBS. Cell pellets were resuspended in 1ml lysis buffer 1 (50 mM HEPES-KOH, pH 7.6,140 mM NaCl,1 mM EDTA, 10% (v/v) Glycerol, 0.5% NP-40,0.25% Triton X-100, complete protease inhibitor cocktail (PIC) (Roche,11697498001) for 10 min at 4^o^C, followed by centrifugation at 1,350 x g for 5 min at 4^o^C. Discard the supernatant and resuspend the pellet in 1 ml of lysis buffer 2 (10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, PIC) for 10 min in at 4^o^C, followed by centrifugation at 1,350 x g for 5 min at 4 ^o^C. Finally resuspend the cell pellet in 700 µl of lysis buffer 3 (10 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% sodium deoxycholate, 0.5% N-Lauroylsarcosine, 1X PIC) and sonicate to desired length using Bioruptor (UCD-200; Diagenode, Denville, NJ) for 30 min \[10 min x 3 times (each cycle consists of 30 s on, 30 s off) at high settings\]. Clarify the lysates by centrifugation at 10,000 rpm in a microcentrifuge for 10 min at 4^o^C. Transfer the sonicated chromatin to a new tube and store at -80^o^C or use it immediately for chromatin immunoprecipitation (ChIP). We used two sets of chromatin (long and short) for ChIP and library preparation. Long ChIP samples were generated using sonicated chromatin consisting of DNA fragments ranging from sizes 1 kb--500 bp. Short ChIP samples were generated using sonicated chromatin consisting of DNA fragments ranging from sizes 500--200 bp.

First, FLAG-coupled protein G beads were generated by incubating 10 ug of FLAG antibody (Sigma-Aldrich, F1804) with 50 μl of prewashed protein G magnetic beads (NEB S1430S) in PBS/BSA (5 mg/ml) buffer at 4^o^C, overnight. Chromatin Immunoprecipitation is performed by incubating these FLAG-coupled protein G beads with the sonicated chromatin in ChIP buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100) at 4^o^C, overnight. 10% of the total chromatin used for the ChIP is set aside as input sample and stored at -20°C until further use. The magnetic beads were washed twice with ChIP buffer, once with ChIP buffer containing 500 mM NaCl, four times with RIPA buffer (10 mM Tris-HCl pH 8.0, 0.25 M LiCl, 1 mM EDTA, 0.5% NP-40, 0.5% sodium deoxycholate), and once with TE buffer (10 mM Tris-HCl,pH 8.0, 1 mM EDTA). Finally elute DNA from the beads by adding 100 µl of elution buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 20 mM EDTA, 1% SDS) twice and incubating for 15 min at 65°C. The eluted DNA and the input samples were then reverse crosslinked at 65^o^C for overnight, followed by RNase A(0.2 mg/ml) digestion at 37^o^C for 2 h and Proteinase K (0.2 mg/ml) (NEB, P8102S) digestion at 55^o^C for 1 hr. The ChIP and input DNA were recovered by phenol-chloroform extraction and ethanol precipitation.

ChIP-seq Library preparation {#s4-14}
----------------------------

ChIP samples were end-repaired, A-tailed and adaptor ligated using barcode adaptors. Briefly, DNA was end-repaired using a combination of T4 DNA polymerase, E. coli DNA Pol I large fragment (Klenow polymerase) and T4 polynucleotide kinase. The blunt, phosphorylated ends were treated with Klenow fragment (exo minus) and dATP to yield a protruding 3- \'A\' base for ligation of barcoded adapters which have a single \'T\' base overhang at the 3' end. DNA purification on Qiagen mini elute columns was performed following each enzyme reactions. The adaptor ligated material was then PCR amplified with Phusion polymerase using 16 cycles of PCR before size selection of 200--350 bp fragments on a 2% agarose gel. The ChIP-seq library samples were purified using Qiagen gel extraction kit, and its concentration was determined on Agilent Bioanalyzer using High Sensitivity DNA chip (Agilent Technologies, Santa Clara, CA). Libraries with different barcodes were multiplexed together at equimolar concentrations and single-end sequencing (50 bp) was performed at Center for Advanced Technology, genomics core facility, UCSF. Each lane of the HiSeq 2000 (Illumina, San Diego, CA) had five libraries (four ChIP DNA and one input DNA) multiplexed with barcodes added to the 5\' end of the sequence.

ChIP-seq data analysis {#s4-15}
----------------------

Reads were identified and then mapped to the mm9 assembly of the mouse genome using the Bowtie aligner ([@bib24]). Normalized and background-corrected measures of ChIP signal were created by randomly choosing 10 million unique tags from each dataset, calculating the tag density within 75 bp of each 20 bp bin of the mm9 assembly mouse genome, and then subtracting the matched 10-million-tag-normalized input tag density from each dataset. UCSC genome browser was used to visualize the ChIPseq peaks.

All ChIP-seq peaks present in both the long and short biological replicates were used for motif analysis. Motifs were identified by running MEME ([@bib3]) on fS248A-Tg mESC peaks (-dna -mod zoops -nmotifs 3 -minw 6 -maxw 30 -time 6058 -revcomp -maxsize 1000000). De novo motifs were matched to known motifs using Tomtom ([@bib18]).

The ChIP-seq and microarray data discussed in this publication have been deposited in NCBI\'s Gene Expression Omnibus and are accessible through GEO Series accession number GSE69594 ([http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE 69594](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE%2069594)).

Relative quantitation of AP staining {#s4-16}
------------------------------------

Cells were stained for AP activity as previously described above. NIS-Elements Basic Research software automatically acquired the darkness of the staining. Four fields of view for each experiment was taken and averaged to plot the change in darkness between gene of interest knockdown and *Gfp*.
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(**a**) Differentially expressed genes between fSOX2-Tg and fS248A-Tg cells determined by microarray. P-values, absolute fold change and direction of regulation are listed in columns 2, 3, and 4, respectively. (**b**) Proteins, listed by Gene name, found to interact with SOX2 in mESCs in this study. *FLAG/HA IP* (column 1) lists proteins found to specifically interact with SOX2 in either fSOX2-Tg or fS248A-Tg cells but not in haSOX2-Tg cells (FLAG IP control). *fS48A-Tg Int./fSOX2-Tg Int.* (column 2) indicates the log2 fold-enrichment of the SOX2-protein interaction between the two cell lines. *Z-score (fS48A-Tg/fSOX2-Tg)* indicates the enrichment score for a SOX2-protein interaction between the two cell lines. Previously identified SOX2 interactors are listed for the associated references. Full references can be found in the main text. (**c**) Peptides sequences and m/z values used for the targeted analysis described in [Figure 6c](#fig6){ref-type="fig"}. (**d**) Primers used in this study.

**DOI:** [http://dx.doi.org/10.7554/eLife.10647.025](10.7554/eLife.10647.025)
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Panning B,2016,SOX2 O-GlcNAcylation alters its protein-protein interactions and genomic occupancy to modulate gene expression in pluripotent cells,<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69594>,Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSE69594).

Panning B, Peddada S,2016,SOX2 O-GlcNAcylation alters its protein-protein interactions and genomic occupancy to modulate gene expression in pluripotent cells\[ChIP-seq\],<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69592>,Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSE69592).

Panning B, Peddada S, Myers SA, Krings G,2016,SOX2 O-GlcNAcylation alters its protein-protein interactions and genomic occupancy to modulate gene expression in pluripotent cells \[array\],<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69593>,Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSE69593).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"O-GlcNAc regulates SOX2 protein-protein interactions and genomic occupancy to control pluripotency gene expression\" for peer review at *eLife*. Your submission has been favorably evaluated by three reviewers, and the evaluation was overseen by a Reviewing editor and Janet Rossant as Senior editor.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript is a very interesting study regarding the role of SOX2-S248 *O*-GlcNAcylation in the context of ESC differentiation and reprograming. The authors use several functional and genome/proteome-wide assays to investigate the role of *O-*GlcNac in pluripotency and reprogramming by focusing on the transcription factor SOX2.

Myers et al. follow up on their previous observation that the pluripotency factor SOX2 is *O-*GlcNac-modified at Ser-248 in mouse ESCs. Here, they show that *O-*GlcNac-modified SOX2 decreases with differentiation and increases during reprogramming into iPSCs. Ectopic expression of a mutant form of SOX2 that cannot be *O-*GlcNac-modified (S248A) in ESCs supports self-renewal, gives rise to less differentiated colonies and suppresses differentiation. Similarly, ectopic expression of S248A in combination with Oct4, Klf4and c-Myc gives rise to more iPSC colonies than OCT4, SOX2 (WT), Klf4 and c-Myc expression. The authors finally show that ESCs expressing SOX2 S248A form associate with ca. 1,000 loci that are different from WT SOX2 in ESCs and lack nearby OCT4 binding sites. Moreover, proteomic analysis suggests that the S248A form of SOX2 associates less efficiently with PARP1 and other proteins, thus providing a partial explanation for the differentiation defect of mutant ESCs. This study makes a number of interesting observations on a modification that has received a lot of attention in the stem cell field over the last few years. This is an interesting area and this approach is an important one. The manuscript should be acceptable for publication once the authors eliminate the weaknesses outlined below. Various concerns can be addressed by editing text and labels, and by clarifying experimental details in particular with respect to statistics/quantification/replicates. In addition, there is a need for a few additional experiments to confirm the validity of some of the main findings and conclusions, which are perceived by all reviewers as relatively straightforward for the authors.

Essential revisions:

1\) Extracted ion chromatograms are sub-optimal to show quantitative values for peptide abundance since ionization can vary from run to run (i.e. comparing [Figure 1B](#fig1){ref-type="fig"} to 1C). More developed quantitative methods would be much more informative (SILAC, isobaric tagging, etc.). The authors could normalize the area under a peak for a given SOX2 isoform to the area under all SOX2 isoforms to establish relative quantitation; however, the authors would also need to prove that there is no difference in ionization efficiency between WT SOX2 and S248A SOX2. The authors could also use an orthogonal technique such as Western blot if a modification specific antibody is available.

2\) The retention times for the *O-*GlcNAc modified fSOX2-Tg vs. fS248A-Tg is different: is that to be expected for a single amino acid change? Moreover, the authors mention that the asTAD peptide could be modified at T258 with *O-*GlcNAc but do not examine the potential role further. Is this the reason for the residual peak corresponding to an *O-*GlcNAc modified peptide in all of the traces? (i.e., with the S248A cells, one would expect no blue trace otherwise). Importantly, the authors need to address at some level why T258 was not further explored -- they did not make this explicit.

3\) [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}: the authors make conclusions based on this figure, but they do not show statistics. If there is statistical significance associated with the blue and red bars that should be clearly depicted. Moreover, how many times were the experiments in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} performed? It is important to convince the reader and the reviewers that these results are reproducible and give some statistics in the paper.

4\) In the reprogramming experiments, the authors need to show that the SOX2 WT and S248A vectors are expressed at comparable levels. If they are not, this would be a much more trivial explanation for the observed phenotype.

5\) The authors need to better describe and characterize the SOX2-deficient ESC lines (originally made by Masui et al.) harboring SOX2 overexpression constructs, and need to provide more details on how the cell line fSOX2-Tg and F248A-Tg have been created. According to the material method, 2TS22C cells have been stably transfected with CAG-3xF-Sox2 WT or S248A. One reviewer was wondering why the endogenous SOX2 present in the parental line visible on the top WB in [Figure 3B](#fig3){ref-type="fig"} is not expressed in fSOX2-Tg and f248A-Tg? Therefore, the parent cell line setup needs to be explained. The authors should also analyze expression of a few pluripotency markers such as OCT4, SOX2 and NANOG by IF. AP staining is not a quantitative method and should be avoided (regardless, [Figure 3A](#fig3){ref-type="fig"}: AP staining difficult to see).

6\) In [Figure 3B](#fig3){ref-type="fig"}, fSOX2 WT and fSOX2-248A exhibit similar cell localization but localization of endogenous SOX2 in parental cell line should be shown as well to appreciate the physiological localization of the overexpress isoforms of fSOX.

7\) The authors claim that many genes associated with pluripotency are increased in SOX2 S248A mutants as judged by microarrays. It would be helpful to provide GSEA to show that there is an actual enrichment.

8\) Differences in SOX2 occupancy between SOX2 WT and S248 expressing ESCs are rather minimal (ca. 1,000 sites), which could reflect ChIP-to-ChIP variability. It is unclear whether these analyses were done in replicates. The authors need to convincingly show that these differences are real, for example by confirming differentially bound targets by ChIP-PCR using independent cell preparations. Alternatively, the authors could generate ChIP-seq data from biological replicates.

9\) The authors suggest that the SOX2 S248 mutation directs SOX2 to sites that are not co-occupied by OCT4 based on the lack of a canonical OCT4 consensus sequence +/- 20 bp. This would be more convincing if the authors performed ChIP for OCT4 in the SOX2 S248 cells and showed that it does not co-occupy the sites.

10\) Differences in protein-protein binding between SOX2 WT and S248A cells also need to be validated in a more quantitative manner. It is difficult to ascertain how robust the differences presented in [Figure 6](#fig6){ref-type="fig"} really are. Has the MS and validation experiment been performed on the same sample or in biological replicates? In the second paragraph of the subsection "SOX2^S248A^ has altered protein-protein interactions", the authors mention a 4-fold increase in binding partners but give no indication of how this quantitative value was calculated. Moreover, [Figure 6D](#fig6){ref-type="fig"} is a nice experiment to show that GlcNAcylation of SOX2 impairs its interaction with PARP1. However, loadings of SOX2 are not equal throughout the lane and the controls are missing. The authors should show the rate of SOX2 GlcNAcylation that is achieved in here. Also, it is obvious that OGT will interact with SOX2 but this interaction itself may impact the interaction of SOX2 with PARP1. A good control in here would be to incubated SOX2, PARP1 and OGT in presence or not of UDP-GLCNAc.

11\) There are a number of typos that are apparent in the figures as well as throughout the text (e.g., [Figure 1B:](#fig1){ref-type="fig"} *O-*GlcNAc -- the \"O\" is a box; [Figure 1C](#fig1){ref-type="fig"}, there is no top number on the y-axis, [Figure 1C](#fig1){ref-type="fig"} text: μM is μm rather than the \"micro\", F1a the double *O-*GlcNAc peptide is mislabeled. [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, pictures are shifted... It also appears that tables are missing?

12\) Corresponding mass-spectra of the data presented in [Figure 2B](#fig2){ref-type="fig"}, [Figure 2C](#fig2){ref-type="fig"}, [Figure 3C](#fig3){ref-type="fig"}, [Figure 3D](#fig3){ref-type="fig"} are missing and should be provided.

13\) [Figure 1B](#fig1){ref-type="fig"}/C, 2B/C, 3C/D: the x-axis is labeled with RT, but there is no indication of the values associated with the retention time. This does not give the reader a good indication of how narrow a window the authors are examining. Moreover, [Figure 1B and C](#fig1){ref-type="fig"} appear to be stretched. Why is there a y ion annotated in [Figure 1---figure supplements 4](#fig1s4){ref-type="fig"} and [5](#fig1s5){ref-type="fig"}? Is this from a secondary reaction and if so, why are they annotated? Other contaminating peaks that are much larger remain un-annotated.

14\) *O-*GlcNAc modification of OCT4 has also been shown to be required for maintaining pluripotency. \[Cell Stem Cell 17 May 2012 (doi: 10.1016/j.stem.2012.03.001)\] While the authors reference this paper, they do not do so in the context of their OCT4 discussion and this is an important addition for the reader to best understand the state of the field.

15\) The paper is solid but needs to be rewritten in parts to reflect what was actually tested and verified. Certainly SOX2 plays a key role in the maintenance of pluripotency and *O-*GlcNAc influences its function. A suggestion for the title may be: *O-*GlcNAc influences the protein-protein interactions mediated by the pluripotency factor SOX2. It is important that the authors do not leave the impression that this is a unique or sole means by which *O-*GlcNAc influences this important biological process. Moreover, it is important to be concise -- for instance what does \'more pluripotent\' stand for? Thus, the manuscript and the figures should be edited carefully throughout.

16\) As the authors say, the phenotype of the S248A overexpression mutant is counterintuitive given the requirement for OGT in ESCs. I do not think that different contexts can explain this discrepancy, as the authors suggest, since both studies examine ESC self-renewal. It is more likely that the OGT KO phenotype is due to other *O-*GlcNac-modified proteins that have opposing effects to SOX2.

10.7554/eLife.10647.033

Author response

*1) Extracted ion chromatograms are sub-optimal to show quantitative values for peptide abundance since ionization can vary from run to run (i.e. comparing [Figure 1B](#fig1){ref-type="fig"} to 1C). More developed quantitative methods would be much more informative (SILAC, isobaric tagging, etc.). The authors could normalize the area under a peak for a given SOX2 isoform to the area under all SOX2 isoforms to establish relative quantitation; however, the authors would also need to prove that there is no difference in ionization efficiency between WT SOX2 and S248A SOX2. The authors could also use an orthogonal technique such as Western blot if a modification specific antibody is available.*

With modern high mass accuracy and high resolution mass spectrometers, coupled with high performance chromatography label free quantitation (LFQ) has become a powerful method of quantitation. This is especially true for less complex mixtures, such as co-immunoprecipitations or single proteins. We chose LFQ for this study because a majority of our analyses are not comparing isobaric peptides, the wild-type vs. the S248A peptides, for example. However, your point about the ionization efficiencies is very important. We have now included our LC-MS analysis of wild-type and S248A TAD synthetic peptides, as well the GlcNAc-S248 TAD synthetic peptide ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). These analyses show that the ionization efficiency between all the synthetic peptides are roughly equal.

*2) The retention times for the O-GlcNAc modified fSOX2-Tg vs. fS248A-Tg is different: is that to be expected for a single amino acid change? Moreover, the authors mention that the asTAD peptide could be modified at T258 with O-GlcNAc but do not examine the potential role further. Is this the reason for the residual peak corresponding to a O-GlcNAc modified peptide in all of the traces? (i.e., with the S248A cells, one would expect no blue trace otherwise). Importantly, the authors need to address at some level why T258 was not further explored -- they did not make this explicit.*

The change in retention time between the wild-type and S248A peptides is expected. Removal of the hydroxyl group by changing the serine to alanine creates a less hydrophilic peptide. Our synthetic peptide analyses recapitulate the change in retention times between wild-type and mutant peptides.

The role of the other *O-*GlcNAc sites, while potentially interesting, was not the focus of this study. We did not examine the function of the T258 and S259 sites because they had already been studied by Jang et al. (Cell Stem Cell, 2012, Figure S4G). Jang et al. used an *O-*GlcNAc site prediction algorithm that identified T258 and S259 as potential sites. They performed reprogramming analysis with the double T258 and S259 mutant and showed a decrease in efficiency, while mutation of S248+T258+S259 exhibited normal efficiency. The loss of function phenotype of the T258+S259 mutant could be a result of impacting *O-*GlcNAcylation or perturbing protein structure. Since we had a gain of function phenotype with S248 alone and the Jang et al. triple mutant data also suggested a gain of function, we instead chose to focus on this modification site.

*3) [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}: the authors make conclusions based on this figure, but they do not show statistics. If there is statistical significance associated with the blue and red bars that should be clearly depicted. Moreover, how many times were the experiments in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} performed? It is important to convince the reader and the reviewers that these results are reproducible and give some statistics in the paper.*

We now include statistics and the number of replicates in the figure supplement.

*4) In the reprogramming experiments, the authors need to show that the SOX2 WT and S248A vectors are expressed at comparable levels. If they are not, this would be a much more trivial explanation for the observed phenotype.*

We now include Western blotting and immunostaining data showing that SOX2 and S248A are expressed at comparable levels at day 6 of reprogramming ([Figure 2F](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).

*5) The authors need to better describe and characterize the Sox2-deficient ESC lines (originally made by Masui et al.) harboring Sox2 overexpression constructs, and need to provide more details on how the cell line fSOX2-TG and F248A-Tg have been created. According to the material method, 2TS22C cells have been stably transfected with CAG-3xF-SOX2^WT^ or S248A. One reviewer was wondering why the endogenous SOX2 present in the parental line visible on the top WB in [Figure 3B](#fig3){ref-type="fig"} is not expressed in fSOX2-Tg and f248A-Tg? Therefore, the parent cell line setup needs to be explained. The authors should also analyze expression of a few pluripotency markers such as OCT4, SOX2 and NANOG by IF. AP staining is not a quantitative method and should be avoided (regardless, [Figure 3A](#fig3){ref-type="fig"}: AP staining difficult to see).*

The transgenic line originally made by Masui et al. has both endogenous copies of *Sox2* deleted, and a transgenic copy of the *Sox2* cDNA driven by tetracycline-repressible promoter is the sole source SOX2 (Masui et al. Nat Cell Bio, 2007). For our studies we introduced CAG-3xF-SOX2^WT^ or S248A under tet-repressed conditions, selecting for lines with levels of FLAG-tagged SOX2/S248A comparable to the amount of SOX2 in the original parental line (before repression). All experiments are carried out with the tet-SOX2 transgene repressed, which is why untagged SOX2 is no detectable in the blots in [Figure 3A](#fig3){ref-type="fig"}. In the revised manuscript we provide a more detailed description of the generation of our transgenic ESC lines and include a new supplemental figure explaining the method ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In addition, we now include Western blotting/IF for OCT4 and NANOG, showing that these are not substantially different between 3xF-SOX2^WT^ and 3xF-S248A mESCs.

We provide the NANOG, SOX2, and OCT4 immunostaining experiments requested by the reviewer, showing that the wild-type and mutant are not notably different for expression of these pluripotency transcription factors. We have also reduced the intensity of the AP staining to better show colony morphology.

*6) In [Figure 3B](#fig3){ref-type="fig"}, fSOX2 WT and fSOX2-248A exhibit similar cell localization but localization of endogenous SOX2 in parental cell line should be shown as well to appreciate the physiological localization of the overexpress isoforms of fSOX.*

We apologize that the writing in our initial submission was not clear enough about how the ESC lines were generated. The 3xF-SOX2^WT^ and 3xF-S248A mESCs express SOX2 at levels comparable to the parental line by Western blotting ([Figure 3A](#fig3){ref-type="fig"}) and exhibit similar localization (new panel in revised [Figure 3B](#fig3){ref-type="fig"})

*7) The authors claim that many genes associated with pluripotency are increased in SOX2 S248A mutants as judged by microarrays. It would be helpful to provide GSEA to show that there is an actual enrichment.*

We performed GSEA to examine whether self-renewal and/or differentiation genes exhibited preferential alteration in gene expression, and the analyses do not indicate that these pathways are substantially impacted by the S248A mutation. We have reworded the text to reflect this new analysis.

*8) Differences in SOX2 occupancy between SOX2 WT and S248 expressing ESCs are rather minimal (ca. 1,000 sites), which could reflect ChIP-to-O-ChIP variability. It is unclear whether these analyses were done in replicates. The authors need to convincingly show that these differences are real, for example by confirming differentially bound targets by ChIP-PCR using independent cell preparations. Alternatively, the authors could generate ChIP-seq data from biological replicates.*

We apologize that we were not clear enough in our original submission. In the Methods section we indicate that we performed two biological replicates (each with technical duplicates, for a total of 4 replicates) of the ChIP-seq. We now also state that replicates were performed in the figure legend accompanying the text. The files are deposited in GEO and available to the reviewers. Thus the 1000 new sites occupied in mutant relative to wild type (representing a 25% increase in the number of sites) are not likely to be due to ChIP-to ChIP variability.

*9) The authors suggest that the SOX2 S248 mutation directs SOX2 to sites that are not co-occupied by OCT4 based on the lack of a canonical OCT4 consensus sequence +/- 20 bp. This would be more convincing if the authors performed ChIP for OCT4 in the SOX2 S248 cells and showed that it does not co-occupy the sites.*

OCT4 ChIP followed by qPCR at S248A-specific peaks would certainly be informative about whether there is OCT4 binding in the vicinity of these new SOX2 binding sites. ChIP-qPCR doesn\'t provide the type of resolution necessary to indicate where the binding motif lies within the amplicon (in contrast to ChIP-seq, in which read counts indicate SOX2 and OCT4 peaks abut each other in the OCT4-SOX2 motif found in many active promoters in ESCs). Indeed, if we query for OCT4 motifs +/- 100 bp, a substantial fraction of S248A specific sites contain a predicted OCT4 binding site. Therefore, to address whether OCT4 is bound nearby SOX2 at the S248A-specific sites, ChIP-seq will be necessary. Performing such a ChIP-seq experiment is outside the scope of this manuscript, but is certainly something we will pursue in the future. For the resubmission we have changed the presentation of the analysis of ChIP-seq data. Instead of restricting our query to +/-20 bp of the SOX2 peaks, we used de novo motif identification to determine in an unbiased way what motifs predominant in the SOX2 peaks shared by wild type and S248A and in the S248A-specific peaks. Using this method, the canonical SOX2 motif is identified in the S248A-specific peaks and the canonical OCT4:SOX2 motif is identified in the peaks shared between wild type and mutant. This presentation more clearly highlights that mutant SOX2 site specificity is different from that of wild type SOX2.

*10) Differences in protein-protein binding between SOX2 WT and S248A cells also need to be validated in a more quantitative manner. It is difficult to ascertain how robust the differences presented in [Figure 6](#fig6){ref-type="fig"} really are. Has the MS and validation experiment been performed on the same sample or in biological replicates? In the second paragraph of the subsection "SOX2^S248A^ has altered protein-protein interactions", the authors mention a 4-fold increase in binding partners but give no indication of how this quantitative value was calculated. Moreover, [Figure 6D](#fig6){ref-type="fig"} is a nice experiment to show that GlcNAcylation of SOX2 impairs its interaction with PARP1. However, loadings of SOX2 are not equal throughout the lane and the controls are missing. The authors should show the rate of SOX2 GlcNAcylation that is achieved in here. Also, it is obvious that OGT will interact with SOX2 but this interaction itself may impact the interaction of SOX2 with PARP1. A good control in here would be to incubated SOX2, PARP1 and OGT in presence or not of UDP-GLCNAc.*

Forgive our lack of clarity for the affinity purification experiments. Our discovery experiments for the SOX2-protein interactions were performed using well-established, quantitative mass spectrometric methods (Kelihauer et al. MCP, 2015, Sharma et al. Cell Rep, 2014, Schilling et al. MCP, 2012) and is described in the Methods section. Briefly, we used the ratio of a particular protein's intensity to its respective SOX2 intensity, excluding any TAD peptide signal. We then took the ratio of (ProteinX/SOX2-WT)/(ProteinX/SOX2-S248A). The ratios for all proteins were used to determine the variance of the data, and ultimately which proteins were more enriched by WT or mutant SOX2. The discovery work was carried out on biological replicates and IP-Western analyses used additional, separate biological replicates. We have altered the text in a hope to make these points more clear.

Thank you for the kind words regarding the recombinant work. Because concerns were raised about the possibility of a SOX2:OGT interaction impacting the SOX2:PARP1 interaction, we have substantially redesigned the experiment to remove OGT after the *O-*GlcNAcylation reaction. Briefly, we employed Bio-tagged SOX2 and His-tagged OGT for the *O-*GlcNAcylation reaction, carrying out the reaction +/- the sugar donor UDP-GlcNAc. After the reaction, SOX2 was bound to streptavidin beads and isolated away from the OGT (and UDP in the +UDP reaction). The bead bound SOX2 (+/- *O-*GlcNAcylation, confirmed by Western blot and mass spec) was incubated with GST-tagged PARP1, to assay for interaction. In the new figure, we provide appropriate input controls as well as blots showing that OGT is not present in the SOX2-PARP1 pull down.

*11) There are a number of typos that are apparent in the figures as well as throughout the text (e.g., [Figure 1B](#fig1){ref-type="fig"}: O-GlcNAc -- the \"O\" is a box; [Figure 1C](#fig1){ref-type="fig"}, there is no top number on the y-axis, [Figure 1C](#fig1){ref-type="fig"} text: μM is μm rather than the \"micro\", F1a the double O-GlcNAc peptide is mislabeled. [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, pictures are shifted... It also appears that tables are missing?*

We thank the Reviewer for pointing out these oversights. We have made the appropriate corrections.

*12) Corresponding mass-spectra of the data presented in [Figure 2B](#fig2){ref-type="fig"}, [Figure 2C](#fig2){ref-type="fig"}, [Figure 3C](#fig3){ref-type="fig"}, [Figure 3D](#fig3){ref-type="fig"} are missing and should be provided.*

Again, we thank the Reviewer for pointing out this oversight. We have included interactive spectra from one representative experiment for all peptide PTM forms for all subsequent analyses.

*13) [Figure 1B/C](#fig1){ref-type="fig"}, [2B/C](#fig2){ref-type="fig"}, [3C/D](#fig3){ref-type="fig"}: the x-axis is labeled with RT, but there is no indication of the values associated with the retention time. This does not give the reader a good indication of how narrow a window the authors are examining. Moreover, [Figure 1B and C](#fig1){ref-type="fig"} appear to be stretched. Why is there a y ion annotated in [Figure 1---figure supplements 4](#fig1s4){ref-type="fig"} and [5](#fig1s5){ref-type="fig"}? Is this from a secondary reaction and if so, why are they annotated? Other contaminating peaks that are much larger remain un-annotated.*

Thank you for pointing out the loss of RT labels. The figures have been corrected. We have also added annotation to the mass spectra to identify neutral loss and contamination peaks. The y-ion is present because we use supplemental activation during the ETD reaction. Supplemental activation adds a low level of vibrational energy to dissociate ETD product ions that remain associated due to intramolecular interactions (Swaney et al., Anal Chem, 2007, Good et al., MCP, 2007). While the supplemental activation is low enough to not be the major pathway of unimolecular dissociation, some minor collisional activation dissociation can occur.

*14) O-GlcNAc modification of OCT4 has also been shown to be required for maintaining pluripotency. \[Cell Stem Cell 17 May 2012 (doi: 10.1016/j.stem.2012.03.001)\] While the authors reference this paper, they do not do so in the context of their OCT4 discussion and this is an important addition for the reader to best understand the state of the field.*

We did not mention the Jang et al. paper in the context of our OCT4 discussion because we have not been able to reproduce their data. We provide our analysis of OCT4 modification as a supplemental figure, so that others interested in the connection between *O*-GlcNAcylation and pluripotency are aware of the contradictory data.

*15) The paper is solid but needs to be rewritten in parts to reflect what was actually tested and verified. Certainly SOX2 plays a key role in the maintenance of pluripotency and O-GlcNAc influences its function. A suggestion for the title may be: O-GlcNAc influences the protein-protein interactions mediated by the pluripotency factor SOX2. It is important that the authors do not leave the impression that this is a unique or sole means by which O-GlcNAc influences this important biological process. Moreover, it is important to be concise -- for instance what does \'more pluripotent\' stand for? Thus, the manuscript and the figures should be edited carefully throughout.*

These points are well taken. We have gone over the manuscript and made attempts to be more accurate and concise -- 'more pluripotent' is removed. We struggled with how best to word the title so as not to unintentionally convey the idea that *O*-GlcNAc regulates pluripotency entirely through SOX2. We have altered the title to "SOX2 *O*-GlcNAcylation alters protein-protein interactions and genomic occupancy to modulate gene expression in pluripotent cells". This title describes the main results without implying that SOX2 is the only relevant OGT target in pluripotent cells. We feel that is necessary to include "SOX2 *O-*GlcNAcylation...." in the title -- otherwise it could lead to the incorrect impression that the *O-*GlcNAc modification is not necessarily on the SOX2 itself.

*16) As the authors say, the phenotype of the S248A overexpression mutant is counterintuitive given the requirement for OGT in ESCs. I do not think that different contexts can explain this discrepancy, as the authors suggest, since both studies examine ESC self-renewal. It is more likely that the OGT KO phenotype is due to other O-GlcNac-modified proteins that have opposing effects to SOX2.*

This point is absolutely correct. We have removed this discussion point.

[^1]: These authors contributed equally to this work.
